Betrixaban Maleate and Eculizumab

• Generic Name: betrixaban
• Dosage Forms: n.a.
• Other Brand Names: Bevyxxa

Prevention of venous thromboembolism in patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderately or severely restricted mobility and other risk factors for venous thromboembolism.

Pharmacologic thromboprophylaxis generally recommended in patients considered to be at high risk of venous thromboembolism. Anticoagulant prophylaxis recommended by ACCP in acutely ill, hospitalized medical patients at increased risk of thrombosis who are not actively bleeding and do not have an increased risk of bleeding. Such prophylaxis generally continued for 6–21 days until full mobility is restored or hospital discharge, whichever comes first; extended prophylaxis beyond these periods generally not recommended because of data suggesting unfavorable benefit-to-risk ratio for bleeding.

However, available data suggest benefit for extended-duration (35–42 days) betrixaban compared with standard-duration (6–14 days) enoxaparin for reducing risk of venous thromboembolism in hospitalized patients with acute medical illness and reduced mobility, at the cost of an increase in nonmajor but not major bleeding.

Safety and efficacy of betrixaban not established in patients with prosthetic heart valves.

• Generic Name: eculizumab
• Dosage Forms: n.a.
• Other Brand Names: Soliris

Eculizumab is a monoclonal antibody. Eculizumab binds to proteins in the blood that can destroy red blood cells in people with genetic conditions that affect the natural defenses of red blood cells.

Eculizumab is used to prevent the breakdown of red blood cells in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Eculizumab is also used to treat a rare chronic blood disease called atypical hemolytic uremic syndrome (aHUS) in adults and children who weigh at least 11 pounds (5 kilograms).

Eculizumab is also used to treat myasthenia gravis in adults.

Eculizumab is also used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults.

Eculizumab is available only under a special program. You must be registered in the program and understand the risks and benefits of eculizumab.

Eculizumab may also be used for purposes not listed in this medication guide.